Skip to main content
MyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

PNC-27 Dosing Protocol: 10 mg Vial — p53-Derived Anticancer Peptide Guide

PNC-27 p53 residues 12-26 MDM-2 antagonist peptide dosing guide — selective cancer cell membrane disruption via overexpressed HDM-2 binding.

Go to peptide profileCalculate your dose

Quickstart highlights

PNC-27 (Pro-Leu-Ser-Ser-His-Ser-Ser-Ser-Ser-Val-Pro-Ser-Gln-Lys-Thr-Tyr-Gln-Gly-Ser-Tyr-Gly-Phe-Arg-Leu-Asn-Pro) is a 26-amino acid peptide comprising residues 12–26 of human p53 (the MDM-2-binding sequence) fused to a leader sequence from HDM-2.

  • Concentration: 2 mg/mL (10 mg vial + 5 mL bacteriostatic water).
  • At 2 mg/mL: 5 mg = 250 units per daily injection.
  • Hosain et al. 2004: PNC-27 selectively disrupts HDM-2-overexpressing cancer cell membranes in vitro.
  • EXPERIMENTAL: No human clinical trials completed as of 2026. Physician supervision mandatory.
  • Store lyophilized at -20 °C; reconstituted at 2–8 °C, use within 14 days.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-42500125Once daily (morning)2.5 mg — 125 units; starting dose; assess tolerance
5-125000250Once daily (morning)5 mg — 250 units (2.5 mL); research dose; one 10 mg vial provides 2 doses at 5 mg

Your free PNC-27 tracker

  • Dose reminders
  • Injection logging
  • Cycle progress
Create free account Already have one? Sign in

Reconstitution steps

  1. Draw 5 mL bacteriostatic water (two 2.5 mL draws); inject slowly down the vial wall.
  2. Swirl gently until dissolved; do not shake.
  3. Final concentration: 2 mg/mL. At 2 mg/mL: 2.5 mg = 125 units, 5 mg = 250 units (2.5 mL draw).
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

12-week plan

  • 6 vials
  • 84 syringes
  • 30 mL bac water
  • 84 alcohol swabs
Need clinics? See vetted providers →
Advertisement

Protocol overview & cycle notes

Selectively disrupt cancer cell membranes through PNC-27's HDM-2 binding on overexpressing tumor cells, inducing necrotic cell death via membrane pore formation while sparing normal cells with low HDM-2 expression.

Cycle length: 12 weeks on.

Off-cycle: 8 weeks off; assess via relevant monitoring protocol before resuming.

Storage & handling

Lyophilized: store at -20 °C for maximum stability. Reconstituted at 2 mg/mL: refrigerate 2–8 °C; use within 14 days. Protect from light.

Injection & tracking tips

  • Inject subcutaneously in the morning; PNC-27 does not cause sedation.
  • PNC-27 is a membrane-active peptide — the mechanism requires interaction with membrane-bound HDM-2 on cancer cells; systemic SC delivery achieves this via circulation.
  • CRITICAL: PNC-27 is a highly experimental compound with no human clinical trials completed. Use only under direct physician supervision with informed consent about experimental status.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • If monitoring cancer biomarkers: track relevant tumor markers (CA-125, PSA, CEA) per oncologist guidance.
  • Monitor liver function tests (ALT, AST) at baseline and every 4 weeks — membrane-disrupting peptides may cause hepatocyte stress at high doses.
  • Record injection site reactions — PNC-27 may cause local redness and induration due to membrane-active properties.
Log your cycle in the calculator →

How this works & references

PNC-27 (Pro-Leu-Ser-Ser-His-Ser-Ser-Ser-Ser-Val-Pro-Ser-Gln-Lys-Thr-Tyr-Gln-Gly-Ser-Tyr-Gly-Phe-Arg-Leu-Asn-Pro) is a 26-amino acid peptide comprising residues 12–26 of human p53 (the MDM-2-binding sequence) fused to a leader sequence from HDM-2. Hosain et al. (2004, 2007) demonstrated PNC-27 binds HDM-2 overexpressed on cancer cell membranes (not nucleus), forming pores that cause selective necrosis of HDM-2-overexpressing cancer cells while sparing normal cells with low membrane HDM-2. In vitro selectivity demonstrated for breast, pancreatic, and melanoma cells. No published human clinical trials as of 2026.

Sources

  • Source: Hosain SB et al. — PNC-27 kills cancer cells by disrupting the cell membrane. J Biol Chem. 2004
  • Source: Manfredi JJ et al. — PNC-27 anticancer peptide: mechanism review. Cancer Lett. 2020

Frequently asked questions

How selective is PNC-27 for cancer cells versus normal cells?
In vitro data (Hosain et al.) shows >95% cancer cell killing with <5% normal cell toxicity in direct exposure assays. Selectivity depends on membrane HDM-2 overexpression — cancer cells with high membrane HDM-2 are selectively targeted. Normal cells with low or absent membrane HDM-2 are largely spared. Whether this selectivity translates to adequate therapeutic index in humans is unknown — no in vivo human data exists.
What cancers show HDM-2 overexpression (potential PNC-27 targets)?
HDM-2 (human MDM-2) is overexpressed in approximately 7–10% of all cancers. Most common: sarcomas (20–30%), glioblastoma multiforme (15–20%), breast carcinoma (5–10%), melanoma (5%), and adenocarcinomas (varying). Cancers with p53 mutations often have concurrent HDM-2 amplification as an alternative p53 suppression mechanism.
Is PNC-27 safe to use as an adjunct with standard chemotherapy?
No safety data for PNC-27 combination with any standard chemotherapy agent exists in humans. The membrane-disruption mechanism of PNC-27 is distinct from most chemotherapy agents (DNA alkylation, tubulin disruption, topoisomerase inhibition), suggesting non-overlapping toxicity profiles — but this is theoretical. Physician-supervised combination use requires extreme caution given the complete absence of clinical pharmacokinetic and toxicology data.
Why does PNC-27 cause necrosis rather than apoptosis?
Apoptosis requires ATP-dependent caspase activation — a controlled cell death program. PNC-27 causes membrane pore formation on cancer cells, leading to rapid loss of membrane potential and ionic homeostasis. This is necrotic cell death — rapid, energy-independent destruction of membrane integrity. Necrosis releases danger-associated molecular patterns (DAMPs) that may trigger anti-tumor immune responses, a potential advantage versus apoptotic cell death.
Where can I find a physician willing to supervise PNC-27 use?
PNC-27 supervision requires a physician with oncology background willing to oversee experimental compound use. Integrative oncology and functional medicine physicians with cancer treatment experience are most likely to evaluate appropriateness. Full informed consent about experimental status, lack of human trials, and potential unknown risks must be documented before initiation.

Related protocols

KLOW Blend Dosing Protocol — BPC-157, TB-500, KPV & GHK-Cu Guide

KLOW peptide blend (BPC-157 + TB-500 + KPV + GHK-Cu) dosing guide for tissue repair, anti-inflammatory support, and extracellular matrix remodeling — the GLOW blend plus KPV.

View protocol

GLOW Blend Dosing Protocol — BPC-157, TB-500 & GHK-Cu Skin & Repair Guide

GLOW peptide blend (BPC-157 + TB-500 + GHK-Cu) dosing guide for tissue repair, angiogenesis, and collagen and connective-tissue remodeling.

View protocol

Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide

Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.

View protocol

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

View protocol

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Need help?

Browse vetted clinicsView full peptide profile →